Association between IGF-1 levels ranges and all-cause mortality: A meta-analysis
Aging Cell, 2022. Rahmani J, et al.
Funding and competing interests (as published with the paper): AL and VDL have equity interest in a company producing medical food (L‐Nutra). This is not directly but indirectly related to the topic of this meta‐analysis. All other authors declare no competing interests.
- Study type
- Meta-analysis (not about the FMD)
- Journal
- Aging Cell
- Published
- 2022
- Authors
- Rahmani J, et al.
- DOI
- 10.1111/acel.13540
- PubMed ID
- 35048526
Summary
This is a meta-analysis, used here as background and comparison research, not a study of the Fasting Mimicking Diet or Prolon. Researchers combined data from 19 published studies, covering over 30,000 participants, to examine how blood levels of IGF-1, a hormone, relate to all-cause mortality risk.
The authors reported a U-shaped relationship: both low and high IGF-1 levels were associated with increased mortality risk, with a specific middle range (120 to 160 ng/mL) associated with the lowest mortality in the studies analyzed.
This paper does not test the FMD, Prolon, or any dietary intervention. It compared people's measured IGF-1 levels and did not test whether changing IGF-1 changes mortality. It is cited here only as background literature, not as evidence that any product changes IGF-1 or extends life.
A meta-analysis used here as background and comparison research on IGF-1 and mortality. It is not a study of the Fasting Mimicking Diet or Prolon.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.